在胰岛素治疗糖尿病管理中的未满足需求
Irl B Hirsch1, Christopher G Parkin2
1University of Washington Medical School of Medicine, Seattle, Washington, USA.
Diabetes technology & therapeutics
|February 1, 2026
概括
尽管在糖尿病治疗方面取得了进展,但血糖控制仍然不足于最佳水平,从而增加了医疗保健费用. 本综述探讨了有效管理的障碍,以及吸入胰岛素在改善需要食用胰岛素治疗的患者治疗结果方面的潜力.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 糖尿病患病率正在上升,这给美国医疗保健系统带来了重大挑战.
- 尽管有先进的胰岛素疗法和糖尿病技术,但对许多人来说,血糖控制仍然不够理想.
- 不良的血糖管理导致严重的临床后果和不断上升的治疗成本.
研究的目的:
- 在胰岛素治疗糖尿病患者中确定有效的血糖管理的主要障碍.
- 评估吸入胰岛素治疗在优化血糖控制方面的潜在作用.
- 为了解决改善糖尿病管理策略的尚未满足的治疗需求.
主要方法:
- 对当前糖尿病管理策略的文献综述.
- 对胰岛素治疗患者的血糖控制障碍的分析.
- 探索吸入胰岛素的疗效和安全性.
主要成果:
- 尽管技术进步,但低于最佳的血糖控制仍然存在.
- 严重的临床和经济负担与糖尿病并发症有关.
- 吸入胰岛素为特定患者群体提供了潜在的治疗选择.
结论:
- 需要加强治疗策略以改善血糖控制.
- 吸入胰岛素可能为需要食用胰岛素的人提供安全有效的解决方案.
- 优化血糖控制可以减少糖尿病的临床和经济负担.
相关概念视频
Diabetes: Management and Pharmacotherapy
1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
Pathophysiology of Diabetes
3.6K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.6K
Insulin Secretory Vesicles
6.9K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
6.9K
Insulin: The Receptor and Signaling Pathways
3.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
3.2K
Insulin Formulations: Types and Delivery
735
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
735
Insulin: Biosynthesis, Chemistry, and Preparation
1.4K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.4K


